This National Brain Tumor Awareness month, we thank the researchers, donors, volunteers and patient families who, together, are making an impact for over 4,000 children diagnosed with a brain cancer each year.
A resource for families and caregivers, our website contains a wealth of information about brain tumors in children, including types of brain tumors, symptoms, diagnosis, treatment and life after treatment. Learn more by clicking here.
CureSearch is committed to driving the strongest research and delivering treatments to children, faster.
Read about our current DIPG projects below:
- Dr. Crystal Mackall’s clinical trial opened for enrollment in the summer and initiated treatment of patients with DIPG - a devastating brain tumor in children that has a 5-year survival rate of less than 1%.
- Dr. Ranjith Menon Muraleedharan is a CureSearch Young Investigator conducting research at Yale University focused on developing a new therapeutic regimen for the treatment of DIPG
There is an urgent unmet need for new and less toxic children’s cancer treatments. Each year more than 16,000 children in the U.S. alone are diagnosed with cancer. For those who survive, as many as 85% will develop one or more chronic health conditions including secondary cancers, severe musculoskeletal problems, and cardiovascular disease as a result of treatment. Our kids deserve better.
We fund the most promising and impactful research focused on developing new therapies for cancers with low survival, high recurrence, or horrible treatment-related side or late effects.
CureSearch-funded brain cancer research projects include:
- Dr. Ranjit Bindra is conducting a phase 1 clinical trial testing a new treatment for pediatric high-grade glioma that could significantly improve long-term survival rates for this aggressive brain cancer.
- Dr. Crystal Mackall’s clinical trial opened for enrollment in the summer and initiated treatment of patients with DIPG- a devastating brain tumor in children that has a 5-year survival rate of less than 1%.
- Dr. Elias Sayour’s first-in-human, phase I/II clinical trial has developed a novel treatment platform, which leverages the use of clinically translatable nanoparticles (NPs) combined with tumor derived mRNA for pediatric high-grade gliomas, the primary cause of death in children with brain tumors.
- Dr. Ranjith Menon Muraleedharan is a CureSearch Young Investigator conducting research at Yale University focused on developing a new therapeutic regimen for the treatment of DIPG
- As of the conclusion of his CureSearch-funded project, Dr. Raabe has developed resources to progress drug development in DIPG.
- Results of Dr. Gilbertson’s research project contributed to the launch of a phase 1 clinical trial testing combination therapies for malignant brain tumors, directly impacting patients with recurrent, refractory medulloblastoma.
